BridgeBio Pharma announced FDA granted approval to Truseltiq for advanced Cholangiocarcinoma
The FDA granted accelerated approval to infigratinib for previously treated locally advanced or metastatic Cholangiocarcinoma harbors FGFR2 fusion or rearrangement. Infigratinib (Truseltiq; BridgeBio ...
Crohn’s Disease (CD) – Press Release
According to Thelansis, the global Crohn’s disease (CD) market was estimated at ~$6,425 MN in 2020 and expected to reach ~$ 12,346 MN by the end of 2030 (10 years of markets forecasting). They attribu ...
Pulmonary Arterial Hypertension (PAH) – Press Release
Pulmonary Arterial Hypertension (PAH) – Market Outlook, Epidemiology, Market Forecast And Competitive Landscape Report – 2020 To 2030, provides the detailed therapy area landscape comprised of disease ...